Montilet 10mg

Tablet
Montelukast Sodium
Amulet Pharmaceuticals

Other Strength:

Alternative:
- Monocast 10mg
- Mirapro 10mg
- Montene 10mg
- Aeron 10mg
- M-Lucas 10mg
- Reversair 10mg
- Monalast 10mg
- Asmatab 10mg
- Provair 10mg
- Ventilast 10mg
- Mokast 10mg
- Montril 10mg
- Monteluk 10mg
- Mon 10mg
- Monas 10mg
- Odmon 10mg



Montilet
DESCRIPTION:
The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene receptors (CysLT) found in the human airway. Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity.

COMPOSITION:
MONTILET Tablet: Each film coated tablet contains Montelukast Sodium INN equivalent to Montelukast INN 10 mg.

INDICATION:
MONTILET (Montelukast) is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom ‘as-needed’ short-acting -Agonists provide inadequate clinical control of asthma.10 mg tablet only: Asthmatic patients in whom Montilet is indicated in asthma, it can also provide symptomatic relief of seasonal allergic rhinitis. Montilet is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

DOSAGE & ADMINISTRATION:
10 mg Tablet: The dosage for adults 15 years of age and older with asthma, or with asthma and concomitant seasonal allergic rhinitis, is one 10 mg tablet daily to be taken in the evening.

CONTRA-INDICATION:
Hypersensitivity to any component of this product.

ADVERSE EFFECT:
Montelukast appears to be well tolerated. In clinical trials, the most common adverse effect reported was headache, occurring in approximately 18% of patients. Rash, dyspepsia, dizziness, and abdominal pain were all reported in less than 2% of patients. Elevated liver transaminases have been reported with montelukast use, but not at a greater incidence than with placebo. A small percentage of pediatric patients have experienced diarrhea, sinusitis and otitis media during montelukast clinical trials.

PRECAUTION:
Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Patients should be advised to have appropriate rescue medication available.

DRUG INTERACTION:
Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives, terfenadine, digoxin and warfarin. Caution should be exercised, particularly in children, when montelukast is co-administered with phenytoin, phenobarbital and rifampicin.

USE IN PREGNANCY AND LACTATION:
Montelukast is classified as pregnancy category B. The drug has been shown to cross the placenta of pregnant rats and rabbits, but there have been no reports of its use in pregnant women. Montelukast is also known to be excreted into breast-milk, but only limited information is available on the significance of this finding. Caution should be used prior to initiating montelukast therapy in nursing mothers.

STORAGE CONDITION:
Store at a cool and dry place, protected from light and moisture. Keep out of the reach of children.

HOW SUPPLIED:
MONTILET tablet: Box containing 1×10 tablets in Alu-Alu blister pack.

এই পাতাটি ১৬১ বার দেখা হয়েছে